Abbott Laboratories reported third-quarter 2026 comparable sales growth of exactly 7.0 percent, landing squarely in the 6-to-8 percent range and driving the market’s near-certain pricing. The result reflected solid underlying performance across segments, with Medical Devices advancing 7.8 percent on a comparable basis, Diagnostics at 6.4 percent (including contribution from the Exact Sciences acquisition), and Nutrition showing steady mid-single-digit gains. Reported revenue rose 14.5 percent to $13.013 billion, while the company reaffirmed full-year 2026 comparable sales growth guidance of approximately 6.0 percent alongside tightened adjusted EPS targets. With earnings released today, the outcome is effectively confirmed by official financials; the only realistic challenges would involve rare post-audit restatements or definitional disputes over comparable adjustments, both low-probability events given standard reporting practices.